MLN Phenotyping Services for Partners
KALRO and CIMMYT have been screening germplasm against MLN in Kenya since Nov 2012. The dedicated screening facility at KALRO Naivasha was established in 2013. This facility now represents a high-quality phenotyping platform, permitting large-scale screening of germplasm from regional partners (both public and private sectors).
The following table shows the number of entries and rows screened for National Research System (NRS) partners and seed companies since 2014. Partners using the Naivasha screening site in 2015-2020 include:
|Private Seed companies|
MLN Screening is done free of charge for NARS within an established limited number of rows.
** MLN Screening is done on a cost-recovery basis for private sector partners
Summary of MLN phenotyping done at MLN screening facility, Naivasha:
|Partner Type||Entries||Rows||% Rows|
To date, close to 90% of materials screened at Naivasha is susceptible under artificial inoculation. However, resistant / tolerant materials have been identified. Four first generation MLN tolerant /resistant hybrids have been released in East Africa and a further 15-17 second-generation hybrids are at advanced stages of testing.